Oneness Biotech Co (ROCO:4743) EBIT per Share: NT$-2.15 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4743 Oneness Biotech Co Ltd ROCO:4743
57 GF Score
Price NT$46.35
GF Value NT$92.25
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Oneness Biotech Co EBIT per Share?

Oneness Biotech Co ROCO:4743 -3.24% 57 EBIT per Share is NT$-2.15 as of Mar. 2026. GuruFocus rates ROCO:4743 with a GF Score™ of 57/100 and a GF Value™ of NT$92.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,173 Biotechnology companies, Oneness Biotech Co ranks worse than 94.8% on this metric.

Oneness Biotech Co's EBIT per Share for the three months ended in Mar. 2026 was NT$-0.31. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-2.15.

During the past 3 years, the average EBIT per Share Growth Rate was -48.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -7.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was -17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Oneness Biotech Co's EBIT per Share or its related term are showing as below:

ROCO:4743' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -64   Med: -13.15   Max: 20.9
Current: -48.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Oneness Biotech Co was 20.90% per year. The lowest was -64.00% per year. And the median was -13.15% per year.

ROCO:4743's 3-Year EBIT Growth Rate is ranked worse than
94.8% of 1173 companies
in the Biotechnology industry
Industry Median: 15.6 vs ROCO:4743: -48.20

Oneness Biotech Co's EBIT for the three months ended in Mar. 2026 was NT$-147.3 Mil.


Oneness Biotech Co  (ROCO:4743) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Oneness Biotech Co EBIT per Share Related Terms


Oneness Biotech Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for Oneness Biotech Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oneness Biotech Co EBIT per Share Chart

Oneness Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.86 0.97 -2.77 -2.38 -2.18

Oneness Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -1.79 0.01 -0.06 -0.31
ROCO:4743
57GF Score
Oneness Biotech Co Ltd ROCO:4743
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oneness Biotech Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Oneness Biotech Co's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1047.16/479.393
=-2.18

Oneness Biotech Co's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-147.329/480.376
=-0.31

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of NT$-2.15 mean?
Oneness Biotech Co (ROCO:4743) has a EBIT per Share of NT$-2.15 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oneness Biotech Co and its competitors. According to the industry distribution chart, Oneness Biotech Co ranks #1112 out of 1173 companies in the Biotechnology industry, placing it in the top 94.8%.
Is Oneness Biotech Co's EBIT per Share too high?
Oneness Biotech Co's current EBIT per Share is NT$-2.15. Based on the distribution chart, Oneness Biotech Co ranks #1112 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #1112 out of 1173 companies for EBIT per Share. This places Oneness Biotech Co in the lower half of its industry. The industry median EBIT per Share is 15.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.60, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oneness Biotech Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current EBIT per Share is NT$-2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Oneness Biotech Co (ROCO:4743) is currently considered Possible Value Trap. The stock's GF Value™ is NT$92.25, compared to a current price of NT$46.35 — trading 49.8% below its estimated fair value. The current EBIT per Share is NT$-2.15. Oneness Biotech Co's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Oneness Biotech Co (ROCO:4743), the current EBIT per Share is NT$-2.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oneness Biotech Co (ROCO:4743) Overvalued in 2026?

Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued. The current stock price of NT$46.35 is trading 49.8% below its estimated GF Value™ of NT$92.25. GuruFocus considers Oneness Biotech Co to be Possible Value Trap.

Key valuation signals for ROCO:4743:

  • EBIT per Share: NT$-2.15
  • GF Value™: NT$92.25 vs. price of NT$46.35 (49.8% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4743 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oneness Biotech Co Business Description

Address Zhongxiao West Road, No. 66, 35th Floor, Section 1, Zhongzheng District, Taipei, TWN, 100
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
57GF Score

Get the complete analysis for ROCO:4743

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$46.35
Price
NT$92.25
GF Value